A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.
Lenz HJ, Argilés G, de Jonge MJA, Yaeger R, Doi T, El-Khoueiry A, Eskens F, Kuboki Y, Bertulis J, Nazabadioko S, Pronk L, Tabernero J.
Lenz HJ, et al. Among authors: el khoueiry a.
ESMO Open. 2024 Nov;9(11):103729. doi: 10.1016/j.esmoop.2024.103729.
ESMO Open. 2024.
PMID: 39617530
Free PMC article.
Clinical Trial.